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High expression of PDGFR-β 
in prostate cancer stroma is 
independently associated with 
clinical and biochemical prostate 
cancer recurrence
Yngve Nordby1,2, Elin Richardsen3,4, Mehrdad Rakaee4, Nora Ness4, Tom Donnem1,5, 
Hiten R. H. Patel1,2, Lill-Tove Busund3,4, Roy M. Bremnes1,5 & Sigve Andersen1,5
Due to a lack of sufficient diagnostic tools to predict aggressive disease, there is a significant 
overtreatment of patients with prostate cancer. Platelet derived growth factors (PDGFs) and their 
receptors (PDGFRs) are key regulators of mesenchymal cells in the tumor microenvironment, and has 
been associated with unfavorable outcome in several other cancers. Herein, we aimed to investigate 
the prognostic impact of PDGFR-β and its ligands (PDGF-B and PDGF-D) in a multicenter prostatectomy 
cohort of 535 Norwegian patients. Using tissue microarrays and immunohistochemistry, the expression 
of ligands PDGF-B and PDGF-D and their corresponding receptor, PDGFR-β, was assessed in neoplastic 
tissue and tumor-associated stroma. PDGFR-β was expressed in benign and tumor associated stroma, 
but not in epithelium. High stromal expression of PDGFR-β was independently associated with clinical 
relapse (HR = 2.17, p = 0.010) and biochemical failure (HR = 1.58, p = 0.002). This large study highlights 
the prognostic importance of PDGFR-β expression, implicating its involvement in prostate cancer 
progression even in early stage disease. Hence, analyses of PDGFR-β may help distinguish which 
patients will benefit from radical treatment, and since PDGFR-β is associated with relapse and shorter 
survival, it mandates a focus as a therapeutic target.
Prostate cancer (PC) is the most frequent malignancy in men1. Despite a relatively low mortality rate, the 
sheer PC incidence rate makes it the second most common cause of male cancer death in developed countries. 
Differentiation between patients with an aggressive and potentially deadly form of PC versus patients with indo-
lent disease remains a challenge. Contemporary risk stratification leads to a significant overtreatment (radical 
therapy), but possibly also an undertreatment of some patients2–4. There is a definite need for better prognostic 
tools to aid in the prediction of which patients will benefit from curative treatment.
The platelet derived growth factor ligands (PDGFs) and their receptors (PDGFRs) have emerged as key reg-
ulators of cell growth and division, and mediate significant impact on malignant cells and the tumor microenvi-
ronment5. As potent mitogens for cells of mesenchymal origin, the PDGFs are important regulatory proteins for 
fibroblasts, smooth muscle cells and glial cells. They are involved in embryonic development, cell proliferation, 
cell migration and stimulate wound healing in the adult6. In particular, these factors play a significant role in 
angiogenesis in which mutational activation or upregulation of the PDGFs or PDGFRs may lead to uncontrolled 
blood vessel formation and cancer.
There are five different known isoforms of PDGF ligands: PDGF-AA (PDGF-A), PDGF-BB (PDGF-B), 
PDGF-CC (PDGF-C), PDGF-DD (PDGF-D) and AB heterodimer (PDGF-AB)7. These interact in a specific man-
ner with tyrosine kinase receptors of three different isoforms: PDGFR-α α (PDGFR-α ), PDGFR-β β (PDGFR-β ) 
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and α β heterodimer (PDGFR- α β ). The different ligand isoforms have variable affinities for the receptor isoforms 
causing cross reactivity. PDGFR-β is activated by PDGF-B or PDGF-D.
Although several PDGFR inhibitors are approved for clinical use in other cancer types, attempts at PDGFR 
inhibition in PC patients have so far been unsuccessful with no improvement in disease specific survival, despite 
robust pre-clinical results8–10.
Alternations of PDGFRs have been detected in several cancers including pancreatic, ovarian, breast, gastric, 
thymoma, gastrointestinal stromal tumor, osteosarcoma, hepatocellular and hematologic cancers among oth-
ers11–15. In PC, PDGF-D seems to be involved in osteoclastic differentiation and establishment of bone metasta-
sis16. High levels of PDGFR-β in PC tumor stroma and non-malignant prostate tissue have been associated with 
shorter cancer specific survival for PC patients17. However, PDGFR-β expression for PC patients with a localized 
disease and its prognostic value post radical treatment has, to our knowledge, not been previously examined.
In our pursuit of new prognostic biomarkers and potential targets for novel therapeutic strategies, we system-
atically assessed both PC tumor and stromal expression of PDGFR-β and its ligands PDGF-B and PDGF-D, as 
well as associations with clinical outcome in a large multicenter cohort of 535 prostatectomy patients.
Materials and Methods
Patients. 671 patients who underwent radical prostatectomy with curative intent for adenocarcinoma in the 
prostate from 1995 to 2005, were retrospectively identified from the Departments of Pathology at the University 
Hospital of Northern Norway (n = 267), Nordland Hospital (n = 63), St. Olavs Hospital (n = 330) and Levanger 
Hospital (n = 11). Of these, 136 patients were excluded due to (i) previous non-superficial cancer within five years 
of PC diagnosis (n = 4), (ii) radiotherapy to the pelvis prior to surgery (n = 1), (iii) inadequate paraffin-embed-
ded tissue blocks (n = 130), and (iv) lack of follow-up data (n = 1), leaving a total of 535 eligible patients for the 
cohort. None of the patients had received pre-operative hormonal therapy. The cohort is thoroughly described in 
a previous paper18.
We collected relevant data from medical journals involving: Demographical data, age at surgery, previous 
medical history, retropubic or perineal surgery, and preoperative serum PSA level measured immediately before 
surgery. Further, we collected outcome data until the last follow-up date (December 01, 2015) or until patients’ 
death. The surviving patients’ disease-specific outcomes were recorded for a median follow-up of 12.4 years 
(range 1.5–20 years). These data included postoperative PSA values and postoperative therapy (radio-, hormonal- 
and/or chemotherapy). The following endpoints were used: Biochemical failure (BF) defined as postoperative 
PSA ≥ 0.4 or intervention with salvage therapy; Clinical failure (CF) defined as clinically palpable tumor recur-
rence in the prostate bed or metastasis verified by radiology; Prostate cancer specific death (PCD), defined as 
death caused by PC stated in the patients’ journal.
Tissues and tissue microarray construction. Tumor tissues, consisting of formalin-fixed 
paraffin-embedded blocks of prostate tissue from the patients’ prostatectomies, were collected from the archives 
of the pathological departments. One experienced pathologist (E.R.) reevaluated the prostate samples and classi-
fied them according to the updated WHO guidelines19,20. Two pathologists (E.R. and L.T.B.) identified the most 
representative areas of cancer epithelium cells and adjacent stroma. Each area was biopsied with at least two 
0.6 mm cores. The cores were arranged in tissue microarray (TMA) blocks for large-scale analysis. Multiple 4 μ m 
TMA sections were cut with a Micron microtone (HM355S) and stained by specific antibodies for immunohisto-
chemical analysis (IHC). The detailed methodology has been reported previously21.
Immunohistochemistry. Immunohistochemical analysis was performed on Discovery-Ultra immunos-
tainer (Ventana Medical Systems, Tucson, AZ). Slides were deparaffinized in three 8-minute cycles. On-board 
CC1 antigen retrieval incubated for PDGF-D, PDGF-B and PDGFR-β , 32, 24 and 48 minutes respectively. 
Discovery inhibitor (Cat #760–4840) blocked endogenous peroxidase for 8 minutes. The following primary anti-
bodies were loaded: PDGF-D (R&D system, #AF1159, goat, polyclonal, 1/40 dilution), PDGF-B (Sigma, #A81363, 
rabbit, polyclonal, 1/25 dilution) and PDGFR-β (Cell Signaling, #3169, rabbit, monoclonal, 1/25 dilution). The 
slides were incubated for 32 minutes at 37 °C. Antibody dilution buffer (Ventana, #ADB250) were used for all 
antibodies except for PDGF-D where Discovery antibody diluent (Ventana, #760–108) was utilized. Slides were 
developed using corresponding secondary antibody for 20 minutes, followed by 12 minutes HRP amplification for 
PDGFR-β and were detected using ChromoMap DAB (Cat #760–159). Finally, the slides were counterstained to 
detect the nuclei with Ventana Hematoxylin II reagent for 32 minutes, followed by a Bluing reagent for 8 minutes 
and dehydrated, cleared and mounted as in our routine processing.
Two different controls for our staining method were applied. Firstly, control staining of the sections with an 
isotype-matched control antibody without the primary antibody. Secondly, multiple human organ TMA as pos-
itive and negative tissue controls were used to verify the specificity of the staining in every staining procedure. 
Positive tissue controls comprised of colon carcinoma and placenta for PDGFs, while negative tissue controls 
comprised of normal tonsil and brain.
Scoring of immunohistochemistry. One experienced pathologist (E.R) and one experienced oncologist 
trained in assessing histopathological slides (S.A) independently and semiquantatively scored viable parts of each 
anonymized core by light microscopy. The scorers were blinded for each other’s score. Each core was scored by the 
dominant intensity of staining: 0 = no staining; 1 = weak staining; 2 = moderate staining; 3 = strong staining. In 
addition, each core was also scored by density according to the fraction of marker positive cells in stroma: 0 = 0% 
positive cells; 1 = 1–50% positive cells; 2 = 50–75% positive cells; 3 ≥ 75% positive cells. Stroma and epithelium 
were scored independently if the marker was expressed in these compartments. The core was scored as “missing” if 
the core was missing or considered of insufficient quality to score by both observers. A final score for both intensity 
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and density marker expression in both epithelium and stroma for each patient was calculated using the mean 
values of the observers’ scoring of the patients cores. Scoring of IHC cores were dichotomized into low and high 
expressions. Cut-off values was set at median to secure reproducibility and statistically sufficient numbers in each 
group. High or low expression of PDGF-B or PDGF-D were not significantly associated with endpoints for any 
cut-off. For PDGFR-β , there was no expression of the marker in epithelium. In stroma though, there was a hetero-
geneous distribution of density (cut-off 1.50), while there was a relatively high expression of intensity (cut-off 2.25).
Statistical methods. SPSS 23.0.0.0 (Chicago, IL) was used for all statistical analyses. Correlations were ana-
lyzed using Spearman’s rank correlation coefficient. Comparing means of expressions between different tissues 
were analyzed using the non-parametric Wilcoxon signed rank test. Univariate survival curves were drawn by 
the Kaplan-Meier method, and the statistical significant difference between survival curves was assessed by the 
log-rank test. Presentations of the survival curves were terminated at 194 months due to less than 10% of patients 
at risk after this point. For multivariate analyses, the backward conditional Cox-regression analysis was used 
with a probability for stepwise entry at 0.05 and stepwise removal of 0.10. A p < 0.05 was considered statistically 
significant for all analyses.
Ethics. The reporting of clinicopathological variables, survival data and biomarker expressions was con-
ducted in accordance with the REMARK guidelines. This study has been approved by The Regional Committee 
for Medical and Health Research Ethics, REK Nord, project application 2009/1393, including a mandatory reap-
provement January 22, 2016. The committee waived the need for patient consent for this retrospective study. The 
Data Protection Official for Research (NSD) approved the establishment of the database.
Results
Clinicopathological variables and patient characteristics. The patients’ clinicopathological data are 
presented in the first part of Table 1. Median age at surgery was 62 (47–75) years. At the last follow-up, 37% of the 
patients had BF, 11% had CF and 3.4% were dead of PC. Median preoperative serum PSA was 8.8 (range 0.7–104) 
and the median tumor size was 20 mm (2.0–50).
Expressions. For PDGF-D, intensity was scored in both tumor and normal epithelium. Stroma was not 
scored due to weak staining of fibromuscular stroma, and the positive staining in stroma was mainly in lym-
phoid cells. Density of PDGF-D was not scored due to homogenous distribution. While macrophages and lym-
phoid cells were positive stained, fibroblasts did not express PDGF-D. The staining was cytoplasmic and granular. 
PDGF-D was expressed at a higher level in tumor epithelium (mean = 2.13) compared to normal epithelium 
(mean = 1.85, p < 0.001).
For PDGF-B, only intensity was scored as density was homogenously distributed. Stroma could not be scored 
due to an overall strong staining of fibromuscular stroma. Intensity of both tumor epithelium and normal epi-
thelium was scored separately in two groups. PDGF-B expression was overall cytoplasmic in the luminal and 
basal cells of the epithelium. There was no significant difference in PDGF-B expression in tumor epithelium 
(mean = 1.48) versus normal epithelium (mean = 1.52, p = 0.194).
Both intensity and density were scored for PDGFR-β . But since PDGFR-β was not expressed in epithelium, 
only stroma was scored. Both tumor stroma and normal stroma were scored into two separate groups. The stain-
ing was cytoplasmic and granular, and no membrane staining was seen. Intensity of PDGFR-β was higher in 
tumor stroma (mean = 2.35) compared to normal stroma (mean = 1.85, p < 0.001), and staining density was also 
higher in tumor stroma (mean = 1.85) compared to normal stroma (mean 1.28, p < 0.001).
Representative light microscopic examples of PDGFR-β high and low intensity and density are shown in Fig. 1.
Correlations. There was a high intraclass correlation between the two scorers, with a correlation coefficient 
of 0.95 (CI = 0.94–0.95, p < 0.001). None of the biomarkers correlated to any of the clinicopathological variables 
except a weak correlation between mean density of PDGFR-β in stroma and perineural infiltration (r = 0.25, 
p < 0.001). For the cases where there were two valid scores of stroma or epithelium, the intra-case heterogeneity 
was calculated using the intraclass correlation procedure. For intensity of PDGFR-β stroma scores, there was a 
correlation coefficient of 0.78 (CI = 0.37–0.89, p < 0.001) of absolute agreement. For density of PDGFR-β stroma 
scores, the correlation coefficient was 0.79 (CI = 0.65–0.86, p < 0.001).
Univariate analyses. Results from the univariate analyses of the clinicopathological variables are presented 
in Table 1. For BF, significant prognostic clinicopathological factors were pT-stage (p < 0.001), preoperative PSA 
(p < 0.001), Gleason score (p < 0.001), tumor size (p < 0.001), perineural infiltration (p < 0.001), lymphovascular 
infiltration (p < 0.001) and positive surgical margin (p = 0.049) with its subclass non-apical margin (p < 0.001). 
For CF, significant prognostic factors were age (p = 0.038), pT-stage (p < 0.001), preoperative PSA (p = 0.029), 
Gleason score (p < 0.001), tumor size (p < 0.002), perineural infiltration (p < 0.001), vascular infiltration 
(p < 0.001) and positive non-apical margin (p < 0.001). The significant prognostic factors for PCD (not presented 
in tables) were pT-stage (p < 0.001), preoperative PSA (p = 0.003), Gleason score (p < 0.001), perineural infil-
tration (p < 0.001), lymphovascular infiltration (p < 0.001) and positive non-apical surgical margin (p = 0.022).
Statistical analyses found no difference in endpoints with respect to expressions in tumor stroma respective 
normal stroma. Hence, all stromal scorings were pooled. Intensity and density of PDGFR-β in stroma versus 
endpoints in univariate analyses were examined. Results showed that both intensity and density of PDGFR-β 
were correlated to BF and CF, but density yielded stronger results in means of higher hazard ratio (HR) and sig-
nificance than intensity. In addition, a backward Cox regression analysis, comparing intensity and density versus 
endpoints, was performed, and intensity was removed before the last step in the analysis. Hence, we chose to focus 
on expression as density of PDGFR-β in all stromal scorings.
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Results from the univariate analyses of the molecular markers according to BF and CF endpoints are presented 
in Table 1 and Fig. 2. Patients with a high expression of PDGFR-β in stroma had significantly worse outcome 
regarding BF (p < 0.001) and CF (p = 0.001) compared to patients with low expression of PDGFR-β . For PCD (3.4% 
of cases), no significant outcome difference was observed regarding high or low PDGFR-β expression subgroups.
Expression levels of PDGFR-β versus BF and CF stratified according to AJCC (American Joint Committee on 
Cancer) PC stage are presented in Table 2. For BF, high expression of PDGFR-β is associated with a worse out-
come in stage IIB (p = 0.007) and III (p = 0.029). For CF, high expression of PDGFR-β is associated with a worse 
outcome in stage IIA (p = 0.011) and IIB (p = 0.027).
Univariate analyses of PDGF-B and PDGF-D expressions showed no significant associations with BF, CF and 
PCD.
Characteristics







 ≤ 65 years 357 67 77 94
 > 65 years 178 33 70 91
pT-stage <0.001 <0.001
 pT2 374 70 83 97
 pT3a 114 21 61 87
 pT3b 47 9 43 74
Preop PSA <0.001 0.029
 PSA < 10 308 57 81 95
 PSA > 10 221 42 68 89
 Missing 6 1 — —
Gleason <0.001 <0.001
 3 + 3 183 34 83 98
 3 + 4 219 41 77 94
 4 + 3 81 15 70 90
 4 + 4 17 4 58 86
 ≥ 9 35 6 37 65
Tumor Size <0.001 0.002
 0–20 mm 250 47 83 96
 > 20 mm 285 53 68 90
Perineural infiltration <0.001 <0.001
 No 401 75 80 96
 Yes 134 25 60 83
Lymphovascular infiltration <0.001 <0.001
 No 492 92 77 95
 Yes 43 8 47 69
Positive surgical margin 0.049 0.198
 No 249 47 81 96
 Yes 286 53 69 90
Apical positive surgical margin 0.063 0.427
 No 325 61 74 92
 Yes 210 39 77 93
Non-apical positive surgical margin <0.001 <0.001
 No 381 71 82 96
 Yes 154 29 57 85
Surgical procedure 0.466 0.308
 Retropubic 435 81 77 92
 Perineal 100 19 68 95
PDGFR-β in stroma <0.001 0.001
 Low expression 267 50 80 94
 High expression 262 49 70 91
 Missing 6 1
Table 1.  Patient characteristics, clinicopathological variables and expressions of PDGFR-β in 535 prostate 
cancer patients (univariate analyses; log-rank test). Abbreviations: BF = biochemical failure; CF = clinical 
failure; EFS = event free survival in months.
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Multivariate analyses. Results from a multivariate model of clinicopathological variables and biomarkers 
are shown in Table 3. We observed that in addition to clinicopathological variables [pT-stage (p < 0.001), pre-
operative PSA (p = 0.014), Gleason 4 + 3 (p = 0.039), Gleason ≥ 9 (p = 0.018) and positive non-apical margin 
(p = 0.003)], a high expression of PDGFR-β in stroma correlates to a worse BF (HR = 1.58, p = 0.002). For CF, the 
only factors that correlate to a significantly worse outcome are Gleason score (p < 0.001) and high expression of 
PDGFR-β in stroma (HR 2.17, p = 0.010).
Figure 1. Examples of high and low intensity and density of PDGFR-β immunohistochemical staining in 
tissue microarray cores of prostate cancer stroma. 100× (main) and 400× (embedded) magnification.
Figure 2. Kaplan-Meier curves of low and high expression of PDGFR-β in prostate cancer stroma for (a) 
biochemical failure and (b) clinical failure.
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Discussion
We demonstrate a high expression of PDGFR-β in prostate cancer stroma to be independently and significantly 
associated with biochemical and clinical recurrence in PC patients treated by radical prostatectomy. We found the 
mean expression of PDGFR-β to be higher in tumor stroma compared to normal stroma. In our cohort, PDGFR-β 
outperforms well-established prognostic factors like pT-stage, preoperative PSA, tumor size, PNI, lymphovascu-
lar infiltration and positive surgical margin as a prognostic tool. There was no significant difference in clinical 
outcome according to PDGF-B or PDGF-D expression.
Group
10 year EFS (%)









I (n = 43) NS NS
IIA (n = 111) 76 64 0.082 100 92 0.007
IIB (n = 219) 82 64 0.007 98 96 0.026
III (n = 159) 48 29 0.029 NS
IV (n = 3) NS NS
Table 2.  Ten year EFS for patients with low or high levels of PDGFR-β stromal expression in relation to 
prognostic groups of prostate cancer. The stratification of our cohort into prognostic groups are constructed 
according to the American Joint Committee on Cancer (AJCC) TNM system. Abbreviations: EFS = Event free 
survival; NE = No events; NS = Not significant (p > 0.10); expr = expression of PDGFR-β .
Characteristics
BF (200 events) CF (56 events)




 pT3a 1.56 1.07–2.25 0.019
 pT3b 2.46 1.55–3.90 <0.001
Preop PSA 0.014 NS
 PSA < 10 1
 PSA > 10 1.45 1.08–1.95
Gleason 0.064 <0.001
 3 + 3 1 1
 3 + 4 1.19 0.82–1.70 0.360 3.37 1.36–8.37 0.009
 4 + 3 1.59 1.02–2.47 0.039 4.45 1.61–12.3 0.004
 4 + 4 1.98 0.98–4.00 0.058 5.40 1.35–21.7 0.017
 ≥ 9 1.95 1.12–3.38 0.018 15.1 5.83–39.2 <0.001
Tumor Size NS NS
 0–20 mm
 > 20 mm
Perineural infiltration NS NS
 No
 Yes
Lymphovascular infiltration NS NS
 No
 Yes
Non-apical positive surgical 
margin 0.005 NS
 No 1
 Yes 1.57 1.15–2.15
PDGFR-β in stroma 0.002 0.010
 Low expression 1 1
 High expression 1.58 1.18–2.13 2.17 1.20–3.90
Table 3.  Expression of PDGFR-β in prostate tissue as a prognostic factor in 535 prostate cancer patients 
(multivariate analyses; Cox regression with backward conditional model). Abbreviations: BF = biochemical 
failure; CF = clinical failure; NE = not entered into Cox regression due to not significant in univariate analyses; 
NS = not significant and removed by backward model before last step of analyses.
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PDGF pathway studies are scarce in PC and the majority has been performed in vitro. The absence of marker 
studies involving normal and malignant tissues in both epithelial and stromal compartments further underpins 
the need for further investigation in this field. The strengths of our study are the size of our multicenter cohort, the 
long clinical follow-up, and the examination of both tumor epithelium and stroma. In contrast to RT-PCR tech-
niques, IHC markers allow us to visualize and assess the expression of antibodies in situ. Despite the long clinical 
follow-up (mean 12.4 years), the relatively low incidence of clinical recurrence and prostate cancer-specific death 
leaves a relatively low numbers of events. This demonstrates the need for even larger PC studies to properly evalu-
ate these endpoints. This study is biased towards the selected group of patients that are considered healthy enough 
to undergo prostatectomy and towards stages of PC that are perceived as surgically curable.
In a phase II study of the PDGFR-inhibitor SU101 for patients with hormone-refractory PC, PDGFR-β was 
shown by IHC analysis to be upregulated in most primary and metastatic PC cells22. Corroborating our findings, 
Singh et al. revealed, by using a gene microarray on 235 tumor samples, that PDGFR-β is one of at least five genes 
that predict PC recurrence after prostatectomy23.
Hagglof et al. found that a high expression of PDGFR-β in both normal and tumor stroma was associated 
with poor survival and advanced disease in a natural course of the disease, without radical intervention17. Their 
study was based on PC tissue specimens collected from approximately 300 patients subjected to transurethral 
resection of the prostate (TURP) during 1975–1991. As radical treatment had not been implemented as medical 
practice at the time, their sampled TURP material differs from the intervention prostatectomies of our study. 
Our results show that high expression of PDGFR-β is a prognostic factor after prostatectomy intervention with 
curative intent, and as such unveils the importance of PDGFR-β expression at a more relevant clinical setting. 
While Hagglof et al. did not observe significant prognosticators in the multivariate analysis, our multivariate 
results showed that Gleason score and expression of PDGFR-β were independent significant prognostic factors 
for clinical failure. Although the clinical setting is different from the study by Hagglof et al., our results build on 
their results and demonstrate that PDGFR-β in either benign or malignant stroma of PC tissue is a prognostic 
biomarker both in the natural history of PC and after prostatectomy.
When investigating the ligands PDGF-B and PDGF-D, PDGF-D was expressed at a higher level in tumor 
epithelium compared to normal epithelium. Other studies have suggested that PDGF-D seems to be involved 
in development of bone metastasis, and is associated with increased Gleason and tumor stage24,25. However, we 
found no associations between expression of PDGF-D and clinical outcome. A reason for this may be that our 
sample selection consists of patients with localized disease, whereas earlier studies of PDGF-D have been studies 
implicating a more advanced disease26. Our results indicate that PDGF-D is not significantly associated with 
cancer relapse in earlier stages of the disease.
We found no difference in levels of PDGF-B expression in normal versus tumor epithelium, nor was there 
any associations between expressions and prognosis. These findings are supported by previous clinical studies 
demonstrating that both PDGFR-β and PDGF-D are up-regulated in primary prostate cancers and bone metasta-
ses, whereas PDGF-B is not frequently detected in clinical samples27. Hence, it is the upregulation of the receptor 
PDGFR-β that seems to be of clinical significance for patients considered for radical treatment.
In our cohort, the risk of BF increased 58% (HR 1.58) as a result of high PDGFR-β expression in stroma. 
Even more importantly, the only two factors that predict clinical failure in our cohort are Gleason score and 
high expression of PDGFR-β . If fact, high PDGFR-β expression more than doubles the risk of clinical failure. 
Expressions of PDGFR-β have a significant impact on BF and CF for the intermediate risk groups IIA, IIB and III. 
This is of particular interest as we are in desperate need for better prognostic tools in this patient group.
Our results show that both normal and malignant stroma are of clinical importance. The stromal microen-
vironment is an active and important biological compartment. Mediated through direct cell-cell contacts or by 
secreted molecules, there is a continuous and bilateral molecular crosstalk between both normal cells and tumor 
cells of the stromal compartment. Accordingly, minor changes in one compartment may cause dramatic altera-
tions in the whole system28.
Treatment with inhibitors of the PDGF pathways has been established for several cancer types. The tyrosine 
kinase inhibitor (TKI) imatinib is a potent inhibitor of the PDGFR, and is used to treat gastrointestinal stromal 
tumors, some forms of leukemia, and myeloproliferative diseases among others. Despite robust pre-clinical data, 
imatinib has proven ineffective in Phase I and II clinical trials for patients with metastatic castration-resistant PC 
(mCRPC)10. A Phase II trial even showed that PDGFR inhibition with tandutinib was associated with accelerated 
disease progression, hypothesizing that PDGF contributes to the homeostasis of bone metastases from PC8. Other 
attempts of PDGF inhibition in PC has been no more successful29,30.
Although angiogenesis as endothelial sprouting is regarded as a hallmark of cancer development, several stud-
ies have shown primary tumors and metastases to be able to progress without angiogenesis31,32. The concept of 
vascular co-option implies that tumors can obtain blood supply by overtaking the native vasculature and let 
tumor cells migrate along the vessels of the host organ. Intussusception (or splitting angiogenesis) implies the 
mechanism where preexisting vessels split into daughter vessels. These relatively new considerations suggest that 
the vasculature of human tumors is more comprehensive than previously regarded, and have been introduced as 
a potential explanation of antiangiogenic drug resistance.
As a clinically and molecularly heterogeneous disease, the lack of available prognostic biomarkers for PC 
patient stratification regarding therapy is one of the key reasons why several trials have produced disappointing 
results. PDGFR upregulation has been suggested as a mechanism of evading different targeted drug therapies 
in some preclinical studies, and further exploration in a clinical relevant setting is warranted33. Specific prog-
nostic biomarkers, associated with response to therapy, are also warranted in order to guide treatment strati-
fication. There are still several unresolved aspects regarding PDGFR inhibition as PC treatment. Hitherto, no 
studies involving PDGFR-inhibition has been carried out in early stage prostate cancer. According to translational 
research data, it can be speculated that such therapy may prove effective in the primary setting.
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In conclusion, our results indicate PDGFR-β in either benign or tumor associated stroma to be a strong, 
independent predictor of prostate cancer recurrence. Although PDGF inhibition so far has been disappointing, 
its implication in PC relapse warrants further exploration in an optimal setting. As a prognosticator, PDGFR-β in 
PC stroma consistently appears to be associated with poor prognosis, particularly in the important intermediate 
risk subgroups. Prospective validation should be considered for future studies.
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